Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: A pilot open label study

Tremor and Other Hyperkinetic Movements

Volumn 1, Issue 1, 2012, Pages

  Fekete, Robert ^a   Davidson, Anthony ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chorea; Huntington disease; Tetrabenazine

Indexed keywords

TETRABENAZINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY II; BERG BALANCE TEST; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DYNAMIC GAIT INDEX; DYSABILITY AND SYMPTOM SCORE; FEMALE; HUMAN; HUNTINGTON CHOREA; INSTRUMENT VALIDATION; JEBSEN HAND TEST; MALE; MONTREAL COGNITIVE ASSESSMENT; MOTOR PERFORMANCE; OPEN STUDY; PILOT STUDY; PSYCHOLOGIC TEST; STROOP TEST; TOTAL MOTOR SCORE; UNIFIED HUNTINGTON DISEASE RATING SCALE; VALIDATION PROCESS;

EID: 84896732655     PISSN: None     EISSN: 21608288     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8:844-856, http://dx.doi.org/10.1016/S1474-4422(09)70183-8.
2. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurotherap 2011;11: 1509-1523, http://dx.doi.org/10.1586/ern.11.149.
3. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372, http://dx.doi.org/10.1212/01.wnl.0000198586.85250.13.
4. Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985;35:1450-1454, http://dx.doi.org/10.1212/WNL.35.10.1450.
5. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 2002;25:263-5, http://dx.doi. org/10.1097/00002826-200209000-00007.
6. Ferrara JM, Mostile G, Hunter C, Adam OR, Jankovic J. Effect of tetrabenazine (TBZ) on motor function in patients with Huntington disease (HD). In: Program and abstracts of the 64th American Academy of Neurology Annual Meeting, Toronto, Ontario, 2010.
7. Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord 2010;25:401-404, http://dx.doi.org/10. 1002/mds.22748.
8. Steer RA, Ball R, Ranieri WF, Beck AT. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Psychopathol Behav Assess 1999:55:117-128.
9. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142, http://dx.doi.org/10. 1002/mds.870110204.
10. Berg KO, Maki BE, Williams JI, et al. Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil 1992;73: 1073-1080.
11. Berg KO, Wood-Dauphinee SL, Williams JT, Maki B. Measuring balance in the elderly: validation of an instrument. Can J Public Health 1992;83: S7-11.
12. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961-967, http://dx.doi.org/10.1001/archneur.58.6.961.
13. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil 1969;50: 311-319.
14. Beaton DE, Wright JG, Katz JN. Upper extremity collaborative group. Development of the QuickDASH: Comparison of three item-reduction approaches. J Bone Joint Surg Am 2005;87:1038-1046, http://dx.doi.org/10. 2106/JBJS.D.02060.
15. Whitney SL, Hudak MT, Marchetti GF. The dynamic gait index relates to self-reported fall history in individuals with vestibular dysfunction. J Vestib Res 2000;10:99-105.
16. Tian J, Herdman SJ, Zee DS, Folstein SE. Postural stability in patients with Huntington's disease. Neurology 1992;42:1232-1238, http://dx.doi.org/10. 1212/WNL.42.6.1232.
17. Salomonczyk D, Panzera R, Pirogovosky E, et al. Impaired postural stability as a marker of premanifest Huntington's disease. Mov Disord 2010;25: 2428-2433, http://dx.doi.org/10.1002/mds.23309.
18. Scholes KE, Harrison BJ, O'Neill BV, et al. Acute serotonin and dopamine depletion improves attentional control: findings from the Stroop Task. Neuropsychopharmacology 2007;32:1600-1610, http://dx.doi.org/10.1038/ sj.npp.1301262.
19. Sánchez-Pernaute R, Künig G, del Barrio Alba A, de Yébenes JG, Vontobel P, Leenders KL. Bradykinesia in early Huntington's disease. Neurology 2000;54:119-125, http://dx.doi.org/10.1212/WNL.54.1.119.
20. Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000;403:544- 549, http://dx.doi.org/10.1038/35000576.
21. Paleacu D. Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat 2007;3:545-551.
22. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31: 127-133, http://dx.doi.org/10.1097/WNF.0b013e3180ca77ea.
23. Frank S. Tetrabenazine as anti-chorea therapy in Huntington Disease: an open label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurology 2009;9:62, http://dx.doi.org/10.1186/1471- 2377-9-62.
24. Satou T, Anderson AJ, Itoh T, et al. Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of substantia nigra in rats. Exp Toxicol Pathol 2001;53:303-308, http://dx.doi.org/ 10.1078/0940-2993-00195.
25. Butler PD, Edwards E, Barkai I. Imipramine and tetrabenazine: effect on monoamine receptor binding sites and phosphoinositide hydrolysis. Eur J Pharmacol 1989;160:93-100.
26. Chafetz MD, Matthews LH. A new interference score for the Stroop test. Arch Clin Neuropsychol 2004;19:555-567, http://dx.doi.org/10.1016/j.acn.2003. 08.004.